MAZE – maze therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Maze Therapeutics (MAZE) had its price target raised by Wedbush from $43.00 to $58.00. They now have an "outperform" rating on the stock.
Maze Therapeutics (MAZE) was upgraded by Mizuho to "strong-buy".
Maze Therapeutics (MAZE) is now covered by Mizuho. They set an "outperform" rating and a $97.00 price target on the stock.
Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
Maze Therapeutics (MAZE) had its price target raised by Guggenheim from $46.00 to $58.00. They now have a "buy" rating on the stock.
Form 4 Maze Therapeutics, Inc. For: Mar 10 Filed by: Bernstein Harold
Form 144 Maze Therapeutics, Inc. Filed by: Bernstein Harold
Form 4 Maze Therapeutics, Inc. For: Feb 27 Filed by: Dandekar Atul
Form 4 Maze Therapeutics, Inc. For: Mar 02 Filed by: Bachrodt Amy
Form 4 Maze Therapeutics, Inc. For: Mar 02 Filed by: Bernstein Harold
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.